Study of methotrexate for the control of chronic inflammation in sickle cell disease patients

Phase 2

• Conditions: Patients with Sickle cell disease; D57.0

• Registration Number: RBR-2s9xvn
• Lead Sponsor: Centro Infantil Boldrini

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-12-19
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients with sickle cell disease who are under chronic hydroxyurea treatment, have more than 3 vaso-occlusive crises per year, and who experience a current vaso-occlusive crisis that is refractory to opioids for a period longer than 3 weeks. Patients should be older than 18 years. Patients must have signed the Informed Consent Form.

Exclusion Criteria

Pregnancy. Ongoing infection at recruitment into the study.

Study & Design

• Study Type: Intervention
• Study Design: Not specified